Veradigm Stock

Veradigm EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Veradigm (MDRX) as of Aug 17, 2026 is -17.28. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -7.50 — a change of 130.23% (lower).

EV/EBIT

-17.28

YoY

130.23%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Veradigm is 2026 -17.28 . EV/EBIT (Enterprise Value to EBIT) of Veradigm was 2025 -7.50 . It decreases by 130.23% lower compared to the previous year.

The Veradigm EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2018
-17.79 base
Jan 1, 2019
-16.18 base
Jan 1, 2020
-37.78 base
Jan 1, 2021
29.28 base
Jan 1, 2022
-31.66 base
Jan 1, 2024
-46.37 base
Jan 1, 2025 (e)
133.08 base
Jan 1, 2026 (e)
140.58 base
YEARPRICE-TO-EBIT
2026 est 140.58
2025 est 133.08
2024 -46.37
2022 -31.66
2021 29.28
2020 -37.78
2019 -16.18
2018 -17.79
2017 210.64
2016 27.62
2015 92.33
2014 -58.75
2013 -21.63
2012 121.40
2011 16.92
2010 22.84
2009 42.68
2008 16.51
2007 7.26
2006 23.33
2005 25.07
2004 53.91
Access this data via the Eulerpool API

Veradigm Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Veradigm's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Veradigm's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Veradigm's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Veradigm grows earnings faster than its peers.

Veradigm Stock analysis

What does Veradigm do? Allscripts Healthcare Solutions Inc is one of the leading companies in the digital healthcare sector in the USA. The company was founded in 1982 and has since become one of the most important providers of IT solutions in healthcare. Allscripts supports healthcare providers in improving patient care and efficiency through the development and provision of innovative software and IT solutions. The business model of Allscripts is based on the development and sale of web-based software solutions for medical documentation and hospital management. These solutions are mainly distributed to hospitals and practices through subscriptions or licenses. Allscripts offers a variety of products that focus on various areas of medical care. One of the main divisions of the company is the electronic health records system (EHR). This system allows for the electronic recording, storage, and management of medical data and information. This enables healthcare providers to quickly and easily access patient information and document important diagnoses and treatments. Another important division of Allscripts is the Revenue Cycle Management (RCM), which optimizes billing and payment processes in hospitals and practices. In addition, Allscripts also offers solutions for telemedicine, including patient portal applications, remote patient monitoring systems, and mobile apps for patients and providers. Allscripts is based in Chicago and employs over 10,000 employees in various countries. The company also maintains partnerships with other companies in healthcare to facilitate and improve the complexity of digital transformation in the healthcare market. This includes companies like Microsoft, who work together with Allscripts on the development of artificial intelligence for healthcare applications. Allscripts' portfolio of offerings is very broad and provides customers with a variety of software solutions for different areas of medical care. The products are particularly characterized by their user-friendly interfaces, flexibility, and scalability. This allows customers to customize the solutions to their specific needs and consider future requirements. However, some products have been criticized for their expandability, poor design, and slow loading times. Recently, Allscripts has made a number of investments in research and development to address these issues and optimize the applications. In summary, Allscripts Healthcare Solutions Inc is considered one of the leading providers of software and IT solutions in healthcare in the USA. Thanks to a wide range of products and close collaboration with partners in healthcare, Allscripts is able to offer its customers innovative and scalable solutions that help them optimize their business processes and improve the quality of their medical care. Veradigm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veradigm stock

EV/EBIT (Enterprise Value to EBIT) of Veradigm is -17.28 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Veradigm changed from -7.50 to -17.28, representing a 130.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Veradigm since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Veradigm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Veradigm

All Key Metrics — Veradigm